Changing Outcomes Through Achievement Emails in COPD Using Routine Healthcare Audits
NCT ID: NCT07181915
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
270 participants
INTERVENTIONAL
2025-12-01
2027-01-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
One proven way to support better prescribing is "audit and feedback." This involves giving GP practices reports showing how their prescribing compares with guidance and with other practices. Audit and feedback can change behaviour, particularly when focused on medicines and when practices have scope to improve.
In West Yorkshire, the NHS Integrated Care Board (ICB) is running a quality improvement project (QIP) to reduce inappropriate prescribing in COPD. Every GP practice already receives regular feedback reports. This study will run within that project.
The research will test whether the type of email sent with these reports influences prescribing. Practices will be randomly assigned to one of two groups:
* Personalised emails: highlighting their own performance, recognising progress, and giving practical suggestions.
* Generic emails: a simple notification that the report is available, with no tailored advice.
All practices will receive the same reports, seven times over one year; only the email wording will differ.
The main outcome will be the change in how many COPD patients are prescribed inhalers that combine a long-acting beta agonist and inhaled corticosteroid (LABA/ICS), which are no longer recommended in COPD. Secondary outcomes will include other COPD prescribing measures identified by a clinical expert panel. The study will also explore factors that might influence effectiveness, such as practice size, deprivation, and COPD caseload.
Data will come from existing NHS sources. The ICB already collects anonymised prescribing data for improvement work. For this study, the data will be pseudonymised so researchers cannot identify practices. The University of Leeds will analyse the results, but the research team will not know which code relates to which practice.
This study will not change patient care directly. All patients will continue with their usual GP treatment. The aim is to understand whether small changes in delivering audit and feedback make it more effective in supporting best prescribing. In the long term, this could improve the safety and quality of COPD care.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Meta-regression of the Cochrane data showed that the effect size of A\&F has remained largely unchanged over the last two decades of study, leading the authors to postulate that there is no longer reasonable clinical equipoise to question if A\&F is effective. However, they also conclude that studies aiming to isolate how A\&F can be utilised most effectively by comparing different A\&F variations are few and far between and that this should be the target of future A\&F research.
A\&F has previously been used successfully within the West Yorkshire Clinical Commissioning Group (CCG) - now replaced by the NHS West Yorkshire Integrated Care Board (ICB) - to effect change on primary care prescribing practices. The ASPIRE cluster Randomised Controlled Trial (cRCT) of A\&F in this region produced a reduction in risky prescribing (odds ratio 0.82), while the CROP quasi-experimental controlled interrupted time series analysis of A\&F correlated with 15,000 fewer patients being inappropriately prescribed opioids over a period of a year compared to controls (35,36). Both studies utilised a similar A\&F design, utilising a theoretical structure based around the Theoretical Domains Framework (TDF) that is ideal for determining the possible perceptions of interventions by its intended targets. They also operated the Behaviour Change Taxonomy (BCT) to describe their employed behavioural change techniques and their intended effects.
The combined Long-Acting Beta Agonist / Inhaled CorticoSteroid (LABA+ICS) inhaler category has been used to treat COPD patients who present with asthmatic features of partially reversible lung function in the past. The most recent Global Initiative for Chronic Obstructive Lung disease (GOLD) guidelines move away from this however, by actively suggesting their use should be discouraged in favour of LABA-Long-Acting-Muscarinic-Antagonist-ICS (LABA-LAMA-ICS) triple inhalers. This is based on two separated studies suggesting LABA-LAMA-ICS inhalers reduced exacerbations of COPD in a subset of patients compared to LABA-ICS. In 2018, an observational study in the UK suggested that LABA/ICS usage in the COPD population was approximately 20%.
Precision feedback is a concept that suggests that aligning feedback messaging to individual, objective performance and goals may improve the performance of audit and feedback to create change. Here we propose to use the opportunity provided by a pre-planned QIP into COPD prescribing in West Yorkshire to undertake a randomised controlled trial to address this question.
The study design is a Randomised Controlled Trial, which is taking place inside a pre-arranged quality improvement project (QIP) that will involve sending digital A\&F feedback reports to all GP practices within West Yorkshire. The intervention element of this RCT will focus on the email that accompanies this digital A\&F feedback reports, where primary care practices within the NHS West Yorkshire ICB region would be randomised to receive their digital A\&F feedback reports alongside either personalised achievement emails, or generic emails only. All participants would take part in the pre-arranged QIP with or without this proposed research going ahead as it has already been agreed by the regional team. Therefore, randomisation will only affect the email that accompanies the A\&F report. Once randomised, each practice will receive 7 A\&F reports over the course of a year alongside their allocated intervention email format.
The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing QIP, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication. The control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice. Examples of these intervention email types have been uploaded with this submission.
The outcome of this study will be a comparison between the proportion of patients with COPD on ICS/LABA inhalers within this primary care region. Secondary outcomes would look at the other markers of COPD prescribing selected for change in the QIP by the expert panel, as detailed in A11. Features that may influence the impact of the A\&F intervention, including practice size, deprivation index, and respiratory disease burden will also be collected. Where available and when a formal data sharing agreement in the form of an organising information document has been signed, NHS Digital commissioning data for care of COPD patients that has been aggregated and pseudonymised at practice-level will also be supplied for analysis by West Yorkshire ICB.
Primary Care practices within NHS West Yorkshire ICB are already required to gain consent from patients to share patient data for quality improvement purposes. West Yorkshire ICB has a pre-arranged data sharing agreement with each individual GP practice for audit and feedback work, which includes permission to share the data with the University of Leeds. The pre-arranged, separate quality improvement project to improve COPD outcomes in the region through audit and feedback will involve the sharing of relevant patient data between primary care practices and the ICB. As part of this quality improvement project, the ICB will anonymise all patient level data, then aggregate this into a practice level data-point. Standard practice for this quality improvement project would then be for the ICB to pseudonymise this practice level data and share this data with the University of Leeds to aid with analysis. The only differences that this Randomised Controlled Trial adds to this process is that pseudonyms will be pre-arranged by the ICB for each practice. The research team will then randomise (using block randomisation via a simple computerised Random Number Generator) each practice pseudonym to receive their audit and feedback report alongside either a personalised achievement letter email, or a generic email. The research team will remain blinded to the identity of which practice has been assigned which pseudonym. However, clearly it is impossible for the ICB and the practices themselves to be blinded to the assignment status of each practice due to the nature of the intervention. The ICB will retain the process of sending out reports by email and post, as would be standard practice in such a quality improvement project.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control GP practice group
A GP practice allocated to the control intervention within the West Yorkshire Integrated Care Board boundary, UK, that is taking part in the pre-planned COPD quality improvement project (ICONIC).
Generic email - control
A generic email delivered to a GP practice alongside a digital feedback report. The generic control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice.
Intervention GP practice group
A GP practice allocated to the personalised email intervention within the West Yorkshire Integrated Care Board boundary, UK, that is taking part in the pre-planned COPD quality improvement project (ICONIC).
Personalised email - Intervention
A personalised achievement email delivered to a GP practice alongside a digital feedback report. The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing quality improvement project, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Generic email - control
A generic email delivered to a GP practice alongside a digital feedback report. The generic control email will be the same text each time for all practices within that arm and will contain no suggestions for improving practice.
Personalised email - Intervention
A personalised achievement email delivered to a GP practice alongside a digital feedback report. The personalised email wording will change based on the achievement of the practice and the content in the feedback reports, which is being distributed as part of the pre-existing quality improvement project, rather than this research study. The recommendations in bullet points within the personalised emails suggesting how to improve care will be informed as relevant succinct summaries of the key guidance contained with the feedback reports, which will be based on either national guidelines or respected published literature. This will be written by the lead researcher for this project (who is the author of the QIP feedback reports themselves) and will be reviewed by the same group that reviews the QIP feedback report content before publication.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* All prescribing outside of the primary care practice setting (such as that occurring through neighbourhood initiatives, hospice-based prescribers, or secondary care) will be excluded.
* Practices that opt-out of the pre-planned COPD prescribing QIP or are outside the boundary of the NHS West Yorkshire ICB.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Leeds
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Owen Thomas
Principle Investigator; GP; NIHR In-Practice Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Owen Thomas, MBBS; MSc
Role: PRINCIPAL_INVESTIGATOR
University of Leeds
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NHS West Yorkshire Integrated Care Board
Leeds, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Paul Carder
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-NCT48
Identifier Type: -
Identifier Source: org_study_id